[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  PRISM MarketView [@PrismMarketView](/creator/twitter/PrismMarketView) on x 4668 followers Created: 2025-07-07 14:04:33 UTC Apogee Therapeutics $APGE shares surged pre-market after its eczema drug APG777 delivered best-in-class results in a Phase X trial. The IL-13 antibody hit all endpoints and could challenge Dupixent, co-developed by @sanofi ( $SNY) and @Regeneron ( $REGN), with less frequent dosing. XXX engagements  **Related Topics** [$regn](/topic/$regn) [$sny](/topic/$sny) [stocks](/topic/stocks) [$apge](/topic/$apge) [sanofi](/topic/sanofi) [stocks healthcare](/topic/stocks-healthcare) [regeneron pharmaceuticals inc](/topic/regeneron-pharmaceuticals-inc) [Post Link](https://x.com/PrismMarketView/status/1942223213108269549)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
PRISM MarketView @PrismMarketView on x 4668 followers
Created: 2025-07-07 14:04:33 UTC
Apogee Therapeutics $APGE shares surged pre-market after its eczema drug APG777 delivered best-in-class results in a Phase X trial. The IL-13 antibody hit all endpoints and could challenge Dupixent, co-developed by @sanofi ( $SNY) and @Regeneron ( $REGN), with less frequent dosing.
XXX engagements
Related Topics $regn $sny stocks $apge sanofi stocks healthcare regeneron pharmaceuticals inc
/post/tweet::1942223213108269549